PubRank

The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg.

PubWeight™: 0.84‹?›

🔗 View Article (PMID 26743157)

Published in Blood Press on January 08, 2016

Authors

Sverre E Kjeldsen1, Krzysztof Narkiewicz2, Thomas Hedner3, Giuseppe Mancia4

Author Affiliations

1: a Department of Cardiology , University of Oslo, Ullevaal Hospital , Oslo , Norway ;
2: b Department of Hypertension and Diabetology , Medical University of Gdansk , Gdansk , Poland ;
3: c Department of Medicine , University of Göteborg, Sahlgrenska Academy , Göteborg , Sweden ;
4: d IRCCS Istituto Auxologico Italiano, University of Milano-Bicocca , Milan , Italy.

Articles citing this ↘

Hypertension: When should we treat hypertension in patients with diabetes? Nat Rev Cardiol (2016) 0.75

Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations : A joint scientific statement from the Austrian Society of Cardiology and the Austrian Society of Hypertension. Wien Klin Wochenschr (2016) 0.75

Articles cited by this ↗

The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials (2014) 3.50

Articles by these authors ⇆

HOPE-3, SPRINT, VALUE and a meta-analysis of trials in patients with diabetes support treatment of hypertension to a target below 140 mmHg. Blood Press (2016) 0.75